ISSN: 0959-4973

Journal Home

Journal Guideline

Anti-Cancer Drugs Q3 Unclaimed

Lippincott Williams and Wilkins Ltd. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Anti-Cancer Drugs is a journal indexed in SJR in Pharmacology and Oncology with an H index of 98. It has a price of 2040 €. It has an SJR impact factor of 0,471 and it has a best quartile of Q3. It is published in English. It has an SJR impact factor of 0,471.

Anti-Cancer Drugs focuses its scope in these topics and keywords: carcinoma, antitumor, modulator, prognostic, drugs, cycle, duct, effects, efficacy, enhances, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Oncology (Q3) Pharmacology (Q3) Pharmacology (medical) (Q3) Pharmacology (medical) (Q3) Cancer Research (Q4)

Price

2040 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

0,471

SJR Impact factor

98

H Index

239

Total Docs (Last Year)

429

Total Docs (3 years)

3431

Total Refs

968

Total Cites (3 years)

428

Citable Docs (3 years)

2.23

Cites/Doc (2 years)

14.36

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Canadian Journal of Physiology and Pharmacology Q3
Behavioural Pharmacology Q3
Cardiology Q3
Pharmacogenomics and Personalized Medicine Q3
Journal of Oncology Pharmacy Practice Q3

Compare this journals

Aims and Scope

Best articles by citations

Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells

Assessment of cyclooxygense-2 expression with 99mTc-labeled celebrex

19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil

Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status

Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour

In-vitro cell tests using doxorubicin-loaded polymeric TiO2 nanotubes used for cancer photothermotherapy

Apoptosis-inducing oxovanadium(IV) complexes of 1,10-phenanthroline against human ovarian cancer

PI3K-d inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells

Zerumbone inhibits growth of hormone refractory prostate cancer cells by inhibiting JAK2/STAT3 pathway and increases paclitaxel sensitivity

Reversine induces autophagic cell death through the AMP-activated protein kinase pathway in urothelial carcinoma cells

Multidrug resistance

Caffeic acid phenethyl ester induces growth arrest and apoptosis of colon cancer cells via the ??-catenin/T-cell factor signaling

SHOW MORE ARTICLES

Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer

The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines

Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications

Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma

Tumour flare reaction in cancer treatments

Gosha-jinki-gan reduced oxaliplatin-induced hypersensitivity to cold sensation and its effect would be related to suppression of the expression of TRPM8 and TRPA1 in rats

Approach to a multiparametric sensor-chip-based tumor chemosensitivity assay

The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells

L-Methionine inhibits growth of human pancreatic cancer cells

Antimelanoma activity of 1,3,4-thiadiazolium mesoionics: a structure-activity relationship study

NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent

Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives